ANPC - AnPac Bio-Medical Science Co., Ltd.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
9.65
-0.05 (-0.46%)
As of 11:06AM EST. Market open.
Stock chart is not supported by your current browser
Previous Close9.70
Open9.80
Bid9.50 x 3200
Ask9.74 x 900
Day's Range9.50 - 9.65
52 Week Range8.86 - 12.18
Volume2,727
Avg. Volume36,980
Market Cap108.15M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • AnPac Bio Files Coronavirus Detection Patent and Initiates Related Research Project
    PR Newswire

    AnPac Bio Files Coronavirus Detection Patent and Initiates Related Research Project

    AnPac Bio-Medical Science Co., Ltd. ("AnPac Bio," the "Company" or "we") (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, today announced that it has filed a provisional patent application on the use of AnPac Bio's novel detection technology, methods and apparatus for coronavirus detection with the US Patent Trademark and Office on February 10, 2020, which could later lead to formal patent applications in China and other countries. AnPac Bio also announced today that it has entered into a project cooperation agreement with a hospital in China to conduct research studies on the ability of AnPac Bio's CDA (Cancer Differentiation Analysis) technology to detect the risk of coronavirus, which is expected to be a very challenging and long term project for AnPac Bio.

  • PR Newswire

    AnPac Bio Gains Two New Insurance Customers

    AnPac Bio-Medical Science Co., Ltd. ("AnPac Bio" or the "Company") (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, today announced that it has gained two new insurance customers in China for its cancer screening and detection tests ("CDA tests") using its cancer differentiation analysis, or CDA, technology.

  • GlobeNewswire

    WestPark Capital announces trading of $16,000,000 IPO for AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC)

    LOS ANGELES, Feb. 03, 2020 -- WestPark Capital, Inc., a member of FINRA and SIPC, a full-service investment bank and securities broker-dealer firm based in Los Angeles, today.

  • GlobeNewswire

    Univest Securities, LLC. Announces Trading of IPO for its Client AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC), Marking the 1st IPO in 2020 Univest Acts as a Joint Book Running Manager

    Univest Securities, LLC, a member of FINRA and SIPC, is a full-service investment bank and securities broker-dealer firm based in New York, today announced the pricing and trading of the initial public offering (“IPO”) for its client AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio” or the “Company”), marking the 1st IPO in 2020 Univest acts as a joint book running manager. AnPac Bio’s ADSs begin trading on The Nasdaq Global Market (“Nasdaq”) on Thursday, January 30th, 2020 under the trading symbol “ANPC”. In addition, AnPac Bio has granted the underwriters a 30-day option to purchase up to 200,004 additional amount of ADSs at the initial public offering price less underwriting discounts.

  • PR Newswire

    AnPac Bio Announces Pricing of Initial Public Offering

    AnPac Bio-Medical Science Co., Ltd. ("AnPac Bio" or the "Company") (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, today announced that it has priced its initial public offering of 1,333,360 American depositary shares ("ADSs") at US$12.00 per ADS for a total offering size of approximately US$16.0 million, assuming the underwriters do not exercise their over-allotment option to purchase additional ADSs. Each ADS represents one Class A ordinary share of the Company. The ADSs are expected to begin trading on the Nasdaq Global Market on January 30, 2020 under the ticker symbol "ANPC."